Stock Price Quote

CONCORD BIOTECH LTD.

NSE : CONCORDBIOBSE : 543960ISIN CODE : INE338H01029Industry : Pharmaceuticals & DrugsHouse : Private
BSE1792.1530.3 (+1.72 %)
PREV CLOSE ( ) 1761.85
OPEN PRICE ( ) 1798.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13920
TODAY'S LOW / HIGH ( )1720.20 1815.00
52 WK LOW / HIGH ( )1370.05 2658
NSE1793.0032.2 (+1.83 %)
PREV CLOSE( ) 1760.80
OPEN PRICE ( ) 1763.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1793.00 (725)
VOLUME 298425
TODAY'S LOW / HIGH( ) 1721.00 1814.40
52 WK LOW / HIGH ( )1345 2664
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984
Management Info
Sudhir Vaid - Chairman Sudhir Vaid - Managing Director
Registered Office

Address 1482-1486 ,Trasad Road,Dholka,
Ahmedabad Dist,
Gujarat-382225

Phone 02714-222604 / 398200

Email complianceofficer@concordbiotech.com

Website www.concordbiotech.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

08Jul Concord Biotech informs about certific
In compliance with Regulation 74(5) of SEBI (Depositories and Participan..
02Jul Concord Biotech makes equity investmen
Concord Biotech has made an equity investment of $1,500 in Stellon Biote..
24Jun Concord Biotech gets EIR from USFDA fo
Concord Biotech has received an establishment inspection report (EIR) fr..
09Apr Concord Biotech gets final approval fr
Concord Biotech has been granted final approval from the United States F..
09Apr Concord Biotech surges after getting f
Concord Biotech is currently trading at Rs 1619.15, up by 21.35 points o..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit1419.373729.65
Gross Profit 1850.94 4958.76
Operating Profit 1998.075507.79
Net Sales 4298.8412000.87

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1381.60 (4.92%)
M.Cap ( in Cr)952.19
Divi's Lab (BSE)
peergroup  6931.80 (0.71%)
M.Cap ( in Cr)184017.51
NGL Fine-Chem (BSE)
peergroup  1251.00 (2.54%)
M.Cap ( in Cr)772.87
Innova Captab (BSE)
peergroup  869.95 (2.46%)
M.Cap ( in Cr)4978.28
Aarti Pharmalabs (BSE)
peergroup  916.65 (1.94%)
M.Cap ( in Cr)8308.02

Shareholding Pattern

MUTUAL FUNDS/UTI 5.16%
PROMOTERS 44.08%
NON-INSTITUTION 37.43%
FI/BANKS/INSURANCE 3.35%
GOVERNMENT 0%
FII 0%

About Concord Biotech Ltd.

Concord Biotech Ltd. was incorporated in the year 1984. Its today's share price is 1792.15. Its current market capitalisation stands at Rs 18748.79 Cr. In the latest quarter, company has reported Gross Sales of Rs. 10169.39 Cr and Total Income of Rs.10507.19 Cr. The company's management includes Hina Patel, Mandayam Chakravarthy Sriraman, Jayaram Easwaran, Amitabh Thakore, Bharti Khanna, Rajiv Agarwal, Arvind Agarwal, Ravi Kapoor, Ankur Vaid, Sudhir Vaid, Sudhir Vaid.

It is listed on the BSE with a BSE Code of 543960 , NSE with an NSE Symbol of CONCORDBIO and ISIN of INE338H01029. It's Registered office is at 1482-1486 ,Trasad Road,DholkaAhmedabad Dist-382225, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloittee Haskins & Sells

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.